|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.42/--
|
企業價值
614.23M
|
資產負債 |
每股賬面淨值
-6.50
|
現金流量 |
現金流量率
0.14
|
損益表 |
收益
0
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
![](../images/dot.bmp)
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |